The percentage of Americans using weight-loss drugs has nearly quadrupled in the past two years, according to Gallup survey results.

A new Gallup survey found that 11% of U.S. adults now take GLP-1 medications for weight loss, up sharply from just 3% in 2024, highlighting the rapid growth of drugs such as Wegovy, Ozempic, Zepbound, and Mounjaro.

Gallup also found that 15% of Americans have used a weight-loss medication at some point, a nine-point increase in just two years, while public awareness of the drugs has climbed to 91%.

The findings, based on a survey of more than 5,000 adults conducted between late May and early June, underscore how quickly GLP-1 medications have become a fixture of American health care.

The poll results also point to what Gallup described as a potentially encouraging public health trend.

The nation's obesity rate has fallen to 36.4% in 2026 from a record 39.9% in 2022, while diabetes diagnoses have leveled off after rising for more than a decade.

Gallup researchers said the decline in obesity appears to track with increased use of GLP-1 medications, though diabetes rates are expected to stabilize rather than fall because the disease is generally a lifelong condition.

The medications work by mimicking hormones that regulate appetite and blood sugar, helping many patients lose significant amounts of weight.

According to The New York Times, obesity specialists were unsurprised by the survey's findings.

"This validates what I think we're all seeing in practice, that it's really dramatically changing how care is happening," Dr. Scott Hagan, an obesity researcher at the University of Washington, told the newspaper.

Gallup found that brand-name medications remain the dominant choice, accounting for 68% of current users.

However, lower-cost compounded versions are gaining traction, with 19% of users taking customized versions of the drugs.

Among patients using compounded medications, roughly one-third said they switched from a brand-name drug, with two-thirds citing cost or insurance coverage as the primary reason.

The Food and Drug Administration has warned that compounded GLP-1 drugs are not FDA-approved and has moved to crack down on mass-produced copycat versions after shortages of brand-name medications eased.

Still, Gallup found that patients generally reported positive experiences regardless of which version they used.

Nearly three-quarters of brand-name and compounded-drug users described the medications as either "effective" or "extremely effective."

The survey suggests GLP-1 drugs have rapidly reshaped obesity treatment in America, becoming widely recognized household names just five years after the FDA approved Wegovy for weight loss.

As prices decline and new formulations enter the market, their use appears likely to continue growing, even as questions remain over insurance coverage, long-term costs, and regulatory oversight.